Reviews past records of bladder cancer patients treated with pembrolizumab or enfortumab vedotin
Looks back at adults with urothelial carcinoma who received pembrolizumab or enfortumab vedotin.
Plain-language title generated from the registry record
Registry title: ARON-2 Study-Multicentric International Retrospective Study
Key facts
- Where
- Province of Macerata, ItalySee the site
Where in Italy
- Ospedale di Macerata, UOC OncologiaProvince of Macerata, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Matteo Santoni
- Trial code
- NCT05290038
- Record updated
- 2 April 2025
- Original description
The ARON-2 study retrospectively analyze patients treated with pembrolizumab as first-line therapy in patients platinum-unfit or as second-line therapy in patients progressed after previous platinum-based chemotherapy. The amendment has been designed to also analyze patients treated with enfortumab vedotin progressed to previous platinum-based chemotherapy and anti-PD-1/PD-L1 inhibitor.Read full original descriptionShow less
ARON-2 Study-Multicentric International Retrospective Study
The ARON-2 study retrospectively analyze patients treated with pembrolizumab as first-line therapy in patients platinum-unfit or as second-line therapy in patients progressed after previous platinum-based chemotherapy. The amendment has been designed to also analyze patients treated with enfortumab vedotin progressed to previous platinum-based chemotherapy and anti-PD-1/PD-L1 inhibitor.
Inclusion: Patients aged >18y; Histologically confirmed diagnosis of UC of upper and/or lower urinary tract; Histologically or radiologically confirmed metastatic disease; Patients treated with at least one of the following:; Treatment with pembrolizumab in patients progressed after previous platinum-based chemotherapy or as first-line therapy in patients platinum-unfit, and at least 1 cycle of pembrolizumab within the period from 1 January 2018 to 30 November 2021; Treatment with enfortumab vedotin in patients progressed to previous platinum-based chemotherapy and anti-PD-1/PD-L1 inhibitor and at least 1 cycle of enfortumab vedotin within the period from June 1st 2022 to July 31st 2023.
Exclusion: Patients without histologically or radiologically confirmed metastatic disease; Patients without histologically confirmed diagnosis of UC.